News

Caretaker Medical Chosen as Finalist to Compete for $350,000 Grand Prize at MedTech Conference

This year brought in a record number of applications with over 1,100 submissions from 54 countries and 42 U.S. states. With less than a 5% acceptance rate, 50 companies were selected to participate in the MedTech Innovator Showcase, with a subset receiving a place in the MedTech Innovator Accelerator. Over four months, 25 Accelerator companies competed for a coveted spot in the Grand Finals. The five finalists are developing medical technology innovations in remote monitoring, patient safety and satisfaction, and prevention:

  • Alva Health (New Haven, CT) is developing a real-time, wearable stroke monitor for older Americans living with high stroke risk.
  • BioDevek (Brookline, MA) is developing an endoscopically-sprayable adhesive hydrogel to seal and protect surgical lesions after polyp removal.
  • Caretaker Medical (Charlottesville, VA ) is developing a wireless finger sensor for continuous “beat by beat” blood pressure and hemodynamics remote monitoring.
  • Cooler Heads Care (San Diego, CA) is developing an affordable wearable device so chemo patients can keep their hair.
  • Nutromics (Brunswick, AUS) is developing a wearable continuous molecular monitoring platform that can track drugs, hormones, metabolites, and proteins.

The final competition will be both live in-person as well as livestreamed on Wednesday, Sept. 29 at 12:00 PM ET during the The MedTech Conference. Viewers will vote online and in-person to decide who takes home the $350,000 Grand Prize and title of MedTech Innovator 2021. Register to watch the competition livestream here.

Recent News

10/20/2026

Supernus Reaches Key Milestone Toward Proposed Merger with Indivior Following Shareholder Approval

Supernus Pharmaceuticals, Inc. welcomed the decisive backing of shareholders today, who formally voted to approve the pending all-stock merger of equals. This vote marks an important milestone toward completing the merger announced in August 2026, with closing anticipated on November 2, 2026, subject to customary closing conditions. Following closing, the combined organization will officially commence …

10/20/2026

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights …

10/16/2026

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), which recently acquired Azora Therapeutics, today announced the appointment of David Rubenstein, M.D., Ph.D. as Chief Scientist. Dr. Rubenstein will lead the Company’s research and scientific strategy, including the continued development of AT177, a proprietary, oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist being developed for the …